Spotlight Pathology, a healthcare technology startup developing artificial intelligence tools for pathology analysis, has secured £1.4 million in seed funding to accelerate the development of its diagnostic software for blood cancers.
The investment will support regulatory approvals and early clinical studies as the company prepares to introduce its platform into clinical environments.
What The Company Does
Spotlight Pathology builds AI-driven software designed to assist pathologists in analyzing digital pathology images used to diagnose blood cancers.
Diagnosing these conditions can be complex, often requiring multiple specialists to review microscopic tissue samples before reaching a final diagnosis. The company’s software is designed to analyze these digital slides and highlight areas of interest that may indicate cancerous changes.
The system integrates directly into existing pathology workflows, allowing clinicians to review AI-assisted insights alongside traditional diagnostic methods.
By helping identify complex cases more quickly, the platform aims to reduce diagnostic delays and support more consistent interpretation of pathology data.
Advertisement
Market Context / Industry Background
Blood cancers, including conditions such as leukemia and lymphoma, can be challenging to diagnose due to the complexity of tissue analysis and the need for specialist expertise.
At the same time, healthcare systems are experiencing increasing demand for pathology services. In the United Kingdom and other countries, pathology departments often face shortages of trained specialists, which can slow the diagnostic process.
Digital pathology and artificial intelligence technologies are increasingly being explored as tools to help address these challenges. AI systems can analyze large volumes of medical imaging data, assisting clinicians by identifying patterns that may require closer review.
These technologies are intended to support medical professionals rather than replace them, helping pathologists prioritize cases and focus their attention on the most complex diagnoses.
Founder / Investor Commentary
Spotlight Pathology was founded by Dr. Richard Byers, a consultant haematopathologist, and Dr. Martin Fergie, an AI specialist with more than 15 years of experience developing healthcare algorithms.
Byers said the company’s goal is to create tools that support pathologists without disrupting established clinical practices.
“Our mission is to support pathologists with tools that fit seamlessly into existing workflows, helping them reach accurate diagnoses faster and with greater confidence,” he said.
He added that the new funding will help move the technology from development into real clinical environments.
“We’re excited to be scaling the business from Daresbury and working alongside partners across the North West and beyond as we move into this next phase.”
Sakura Holloway, Investment Director at the UK Innovation and Science Seed Fund managed by Future Planet Capital, said the company represents a strong example of translating academic research into healthcare technology.
“The team are addressing a critical challenge in blood cancer diagnosis,” Holloway said. “With the right leadership and support in place, the company is well positioned to bring this technology into clinical settings.”
Growth Plans / Use Of Funds
Spotlight Pathology plans to use the £1.4 million funding to progress its AI platform toward regulatory approval and clinical validation.
The company will conduct early clinical trials designed to evaluate how its technology performs in real-world diagnostic workflows.
The funding will also support further development of the platform’s machine learning models and expansion of the company’s technical and operational teams.
By working with healthcare providers and research institutions, Spotlight Pathology aims to refine its software so it can be integrated into pathology departments across the healthcare system.
About Spotlight Pathology
Spotlight Pathology is a healthcare technology company developing artificial intelligence tools for digital pathology analysis. Founded by clinicians and AI specialists, the company builds decision-support software that analyzes pathology images to assist doctors in diagnosing blood cancers. Its platform is designed to help pathologists identify complex cases more efficiently, streamline diagnostic workflows, and support earlier treatment decisions for patients.
